A Single and Multiple Ascending Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of AZD8965 in Healthy Participants (Including Japanese and Chinese Participants) and an Open-label Cohort to Assess the Effect of Food on the Pharmacokinetics of AZD8965 in Healthy Participants

AstraZeneca147 enrolled

Overview

The purpose of this study is to assess the safety, tolerability, and pharmacokinetics (PK) of AZD8965 via single and multiple ascending doses in healthy participants (including Japanese and Chinese participants), and to assess the effect of food on the safety, tolerability, and PK of orally administered AZD8965.

This is a first in human single and multiple ascending dose study. The study consists of 4 parts: Part 1 (single ascending dose \[SAD\]), Part 2 (multiple ascending dose \[MAD\]), Part 3A (Japanese and Chinese SAD), Part 3B (Japanese and Chinese combined SAD and MAD), and Part 4 (Food Effect). Each study part includes a 28-day screening period and a residential period during which participants will be resident at the Clinical Unit from the day before study intervention administration (Day -1) until at least 48-72 hours after the study intervention administration.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

147

Conditions

Healthy Participants

Interventions

Eligibility

Sex: ALLMin age: 18 YearsMax age: 55 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Healthy male and female participants (including Japanese and Chinese participants) with suitable veins for cannulation or repeated venipuncture. * All females of childbearing potential must have a negative pregnancy test at the Screening Visit (serum) and on admission (urine) to the Clinical Unit. * All females of childbearing potential must not be lactating and if heterosexually active must agree to use an approved method of highly effective contraception with low user dependency and their non-sterilized male partners must use a condom, to avoid pregnancy from the time of first administration of study intervention until 20 days after the last dose of study intervention. Females must not use hormonal contraceptives or hormone replacement therapy during the study. * Females of non-childbearing potential must be confirmed at the Screening Visit by fulfilling one of the following criteria: 1. Postmenopausal defined as amenorrhea for at least 12 months following cessation of all exogenous hormonal treatments and without an alternative medical cause and the follicle stimulating hormone (FSH) level is in the postmenopausal range. 2. Documentation of irreversible surgical sterilization by hysterectomy, bilateral oophorectomy, or bilateral salpingectomy. Tubal ligation is not acceptable. * Sexually active fertile male participants with partners of childbearing potential must adhere to the specified contraception methods from the time of first administration of study intervention administration until 20 days after the last dose of study intervention. * Have a body mass index (BMI) between 18 and 30 kilogram (kg)/square meter (m2) inclusive and weigh at least 45 kg. Part 3A and Part 3B (Japanese Participants) * Healthy Japanese participants are eligible based on meeting all of the following: 1. Born in Japan 2. Have 2 Japanese biological parents and 4 Japanese grandparents. 3. Did not live outside Japan for more than 10 years at the time of Screening. Part 3A and Part 3B (Chinese Participants) * Healthy Chinese participants. Participants of Chinese ancestry are eligible based on meeting all of the following: 1. Born in mainland China, Hong Kong, Macau, or Taiwan 2. Have 2 Chinese biological parents and 4 Chinese grandparents as confirmed by the interview. 3. Did not live outside China for more than 10 years at the time of Screening. Exclusion Criteria: * History of any clinically important disease or disorder which may either put the participant at risk or influence the results or the participant's ability to participate in the study. * Chronic or ongoing gastrointestinal, respiratory, hepatic, renal disease, pancreatic disease, diabetes mellitus, or any other condition known to interfere with absorption, distribution, metabolism, or excretion of drugs. * Chronic or ongoing neurological disorder, any clinically important past or ongoing psychiatric disorder which may confound assessment of the potential neurologic effects of this product. * Participants with a history of hypertension or cardiovascular disease. * Any clinically important illness, medical/surgical procedure, or trauma within 4 weeks of the first administration of study intervention. * Participant with chronic infections (e.g., urinary tract infection) or who are at increased risk of infection (e.g., surgery, trauma, severe dental disease, or significant infection). * Participants with a known or suspected defect in the function of the urea cycle, or with family history of a urea cycle disorder in one or more biological relative. * Any abnormal laboratory values and vital signs. * Ongoing acquired or inherited immunodeficiency disorders, including but not limited to human immunodeficiency virus (HIV) or common variable immunodeficiency, or the participant is taking immune replacement therapy. * History of severe allergy/hypersensitivity or ongoing clinically important allergy/hypersensitivity, or history of hypersensitivity to drugs with a similar chemical structure or class to AZD8965.

Outcomes

Primary Outcomes

Parts 1 and 3A: Number of participants with adverse events (AEs) and serious adverse events (SAEs)

To assess the safety and tolerability of AZD8965 following oral administration of single ascending doses to healthy participants.

Time frame: SAEs: From Screening (Day -28) to 5 weeks; AEs: From Day 1 to 5 weeks

Parts 2 and 3B: Number of participants with AEs and SAEs

To assess the safety and tolerability of AZD8965 following oral administration of multiple ascending doses to healthy participants.

Time frame: SAEs: From Screening (Day -28) to 8 weeks; AEs: From Day 1 to 8 weeks.

Part 4: Maximum observed drug concentration (Cmax)